| 000 | 01211 a2200325 4500 | ||
|---|---|---|---|
| 005 | 20250515231832.0 | ||
| 264 | 0 | _c20110125 | |
| 008 | 201101s 0 0 eng d | ||
| 022 | _a2212-3911 | ||
| 024 | 7 |
_a10.2174/157488610792245993 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aBüttel, Isabel C | |
| 245 | 0 | 0 |
_aImmunogenicity and its impact on benefit/risk considerations in the authorisation of biopharmaceuticals. _h[electronic resource] |
| 260 |
_bCurrent drug safety _cOct 2010 |
||
| 300 |
_a287-92 p. _bdigital |
||
| 500 | _aPublication Type: Guideline; Journal Article | ||
| 650 | 0 | 4 | _aAntibody Formation |
| 650 | 0 | 4 |
_aBiological Products _xadverse effects |
| 650 | 0 | 4 |
_aDrug Approval _xorganization & administration |
| 650 | 0 | 4 |
_aDrug Industry _xorganization & administration |
| 650 | 0 | 4 | _aDrug-Related Side Effects and Adverse Reactions |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aLegislation, Drug |
| 650 | 0 | 4 | _aMarketing |
| 650 | 0 | 4 | _aRisk Assessment |
| 700 | 1 | _aVöller, Katrin | |
| 700 | 1 | _aSchneider, Christian K | |
| 773 | 0 |
_tCurrent drug safety _gvol. 5 _gno. 4 _gp. 287-92 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.2174/157488610792245993 _zAvailable from publisher's website |
| 999 |
_c19958769 _d19958769 |
||